Karyopharm Therapeutics Inc. (KPTI) Stock

Karyopharm Therapeutics Inc. is a pharmaceutical company operating in the commercial stage, specializing in the discovery, development, and commercialization of drugs that target nuclear export mechanisms for the treatment of cancer and other diseases. Central to its innovative approach are Selective Inhibitor of Nuclear Export (SINE) compounds, which function by binding to and inhibiting the nuclear export protein XPO1.

The company's flagship product, XPOVIO, is approved in various formulations: in combination with bortezomib and dexamethasone for multiple myeloma, as well as alone or with dexamethasone for heavily treated cases of this disease and for patients with relapsed or refractory diffuse large B-cell lymphoma. Karyopharm Therapeutics Inc. has entered into a strategic license agreement with the Menarini Group, aiming to develop and commercialize NEXPOVIO across Europe, including the United Kingdom, Latin America, and other regions.

In addition to its current treatments, Karyopharm Therapeutics Inc. continues to advance its oral SINE compounds designed to enhance nuclear accumulation of various tumor suppressor and growth regulatory proteins. This innovative strategy underscores the company's commitment to expanding therapeutic options and improving outcomes for patients.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm Therapeutics Inc. operates at the intersection of pioneering research and clinical application. The company's location in the biotechnology hub of Massachusetts facilitates collaboration and innovation in the pursuit of novel treatments that address critical unmet medical needs in oncology and beyond.